Phaseline

Companies › Prescient Therapeutics

Prescient Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Jan 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PTX-100
Peptidomimetic inhibitor of GGTase 1
GGTA1Phase 2CTCLJan 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06854653PTX-100Phase 2CTCLOncologyJan 2028

Targets

GGTA1 (1)

Companies with the same targets

United Therapeutics Xeno Holdings (US), LLC dba ChoironeX

Companies built like this

NanoEcho Syncromune Galecto Biotech VSPharmTech BPGbio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.